Dr. Xiangfei "Scott" Cheng is Sole Founder, CEO & CSO of Allphild Inc.  He is the sole inventor of hundreds of innovative molecules filed in U.S. patent applications. His inventions target cancers, autoimmune diseases, traumatic brain injury (TBI), neurodegenerative disorders, immunomodulation, transplant immune tolerance and lung fibrosis, and include platforms in microRNA (miRNA)-based therapy, synergistic approach combining CAR-T therapy with the novel molecule that modulates gene expression to prevent CAR-T cell exhaustion,  immunotherapy, immunomodulation, cell therapy,  gene therapy,  and more. 

His earlier U.S. patent–filed innovations resonate the foundational principles later honored by the 2024 and 2025 Nobel Prizes in Physiology or Medicine, pioneering the frontiers of targeted immune regulation and precise gene regulation. 

Additionally, he is the sole inventor of U.S. patent-pending artificial intelligence (AI) technologies for drug development, clinical development, and healthcare, as well as an AI-powered device designed to assist individuals with disabilities.

He is a seasoned leader with over 25 years of drug development experience across R&D, small molecules, and biologics. His expertise spans target discovery, preclinical studies, translational medicine, regulatory submissions, clinical development, and product launch through commercialization. Additionally, he applies Quantum Biology approaches to advance the development of transformative therapies. He has authored more than 90 publications.

He holds both an M.D. and a Ph.D.  Over the course of his career, he has held executive leadership roles including Chief Executive Officer (CEO), Chief Medical Officer (CMO), Chief Scientific Officer (CSO), and Senior Vice President (SVP) of Translational Medicine, working in organizations ranging from startups to global enterprises. 

Prior to his industry career, Dr. Cheng held a faculty role at University of Maryland, driving research in immunomodulation, within a division internationally recognized under the leadership of a former President of a leading international medical society  and current Harvard University Professor. He was also actively involved in cancer research at the same university. 

Dr. Cheng specialized in postdoctoral research in Biochemistry and Molecular Biology at Northwestern University, Chicago, USA, under the mentorship of a member of the U.S. National Academy of Sciences (NAS).